Pathophysiology and treatment of stroke: present status and future perspectives

D Kuriakose, Z Xiao - International journal of molecular sciences, 2020 - mdpi.com
Stroke is the second leading cause of death and a major contributor to disability worldwide.
The prevalence of stroke is highest in developing countries, with ischemic stroke being the …

Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension

PM Rothwell - The Lancet, 2010 - thelancet.com
Although hypertension is the most prevalent treatable vascular risk factor, how it causes end-
organ damage and vascular events is poorly understood. Yet, a widespread belief exists that …

Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension

PM Rothwell, SC Howard, E Dolan, E O'Brien… - The Lancet, 2010 - thelancet.com
Background The mechanisms by which hypertension causes vascular events are unclear.
Guidelines for diagnosis and treatment focus only on underlying mean blood pressure. We …

Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke

PM Rothwell, SC Howard, E Dolan, E O'Brien… - The Lancet …, 2010 - thelancet.com
Background Analyses of some randomised trials show that calcium-channel blockers reduce
the risk of stroke more than expected on the basis of mean blood pressure alone and that β …

Essential hypertension

FH Messerli, B Williams, E Ritz - The Lancet, 2007 - thelancet.com
Essential hypertension can be defined as a rise in blood pressure of unknown cause that
increases risk for cerebral, cardiac, and renal events. In industrialised countries, the risk of …

Beta‐blockers for hypertension

CS Wiysonge, HA Bradley, J Volmink… - Cochrane database …, 2017 - cochranelibrary.com
Background Beta‐blockers refer to a mixed group of drugs with diverse pharmacodynamic
and pharmacokinetic properties. They have shown long‐term beneficial effects on mortality …

Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses …

L Rouch, P Cestac, O Hanon, C Cool, C Helmer… - CNS drugs, 2015 - Springer
Background Chronic hypertension, particularly midlife high blood pressure, has been
associated with an increased risk for cognitive decline and dementia. In this context …

Hypertension & dementia: Pathophysiology & potential utility of antihypertensives in reducing disease burden

M Lyon, JL Fullerton, S Kennedy, LM Work - Pharmacology & Therapeutics, 2023 - Elsevier
Dementia is a common cause of disability and dependency among the elderly due to its
progressive neurodegenerative nature. As there is currently no curative therapy, it is of major …

Calcium channel blockers versus other classes of drugs for hypertension

J Zhu, N Chen, M Zhou, J Guo, C Zhu… - Cochrane Database …, 2021 - cochranelibrary.com
Background This is the first update of a review published in 2010. While calcium channel
blockers (CCBs) are often recommended as a first‐line drug to treat hypertension, the effect …

How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis

HA Bradley, CS Wiysonge, JA Volmink… - Journal of …, 2006 - journals.lww.com
Objective To quantify the effect of first-line antihypertensive treatment with beta-blockers on
mortality, morbidity and withdrawal rates, compared with the other main classes of …